These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

107 related items for PubMed ID: 21742513

  • 1. Autocrine production of interleukin-8 confers cisplatin and paclitaxel resistance in ovarian cancer cells.
    Wang Y, Qu Y, Niu XL, Sun WJ, Zhang XL, Li LZ.
    Cytokine; 2011 Nov; 56(2):365-75. PubMed ID: 21742513
    [Abstract] [Full Text] [Related]

  • 2. Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells.
    Wang Y, Niu XL, Qu Y, Wu J, Zhu YQ, Sun WJ, Li LZ.
    Cancer Lett; 2010 Sep 01; 295(1):110-23. PubMed ID: 20236757
    [Abstract] [Full Text] [Related]

  • 3. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
    Wang Y, Li LZ, Ye L, Niu XL, Liu X, Zhu YQ, Sun WJ, Liang YJ.
    Zhonghua Fu Chan Ke Za Zhi; 2010 Sep 01; 45(9):691-8. PubMed ID: 21092551
    [Abstract] [Full Text] [Related]

  • 4. XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma.
    Ma JJ, Chen BL, Xin XY.
    Eur J Obstet Gynecol Reprod Biol; 2009 Oct 01; 146(2):222-6. PubMed ID: 19758744
    [Abstract] [Full Text] [Related]

  • 5. Interleukin-6 signaling regulates anchorage-independent growth, proliferation, adhesion and invasion in human ovarian cancer cells.
    Wang Y, Li L, Guo X, Jin X, Sun W, Zhang X, Xu RC.
    Cytokine; 2012 Aug 01; 59(2):228-36. PubMed ID: 22595649
    [Abstract] [Full Text] [Related]

  • 6. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS, Hua J, Gibb RK, Mutch DG, Herzog TJ.
    Gynecol Oncol; 2004 Jul 01; 94(1):67-73. PubMed ID: 15262121
    [Abstract] [Full Text] [Related]

  • 7. Regulation of HtrA2/Omi by X-linked inhibitor of apoptosis protein in chemoresistance in human ovarian cancer cells.
    Yang X, Xing H, Gao Q, Chen G, Lu Y, Wang S, Ma D.
    Gynecol Oncol; 2005 May 01; 97(2):413-21. PubMed ID: 15863139
    [Abstract] [Full Text] [Related]

  • 8. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines.
    Henkels KM, Turchi JJ.
    Cancer Res; 1999 Jul 01; 59(13):3077-83. PubMed ID: 10397248
    [Abstract] [Full Text] [Related]

  • 9. Bcl-xL is expressed in ovarian carcinoma and modulates chemotherapy-induced apoptosis.
    Liu JR, Fletcher B, Page C, Hu C, Nunez G, Baker V.
    Gynecol Oncol; 1998 Sep 01; 70(3):398-403. PubMed ID: 9790794
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Study of bcl-2 antisense oligodeoxynucleotides on reversal of cisplatin resistance in ovarian cancer cell line A2780/DDP].
    Li M, Yu LL, Cai LQ, Wang HB, Wang ZH, Wang ZH.
    Zhonghua Fu Chan Ke Za Zhi; 2006 Feb 01; 41(2):121-5. PubMed ID: 16640863
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Role of apoptosis-associated genes and caspase-3 in cisplatin-resistant human ovarian cancer cell lines].
    Yang XK, Xing H, Zheng F, Gao QL, Wang W, Lu YP, Ma D.
    Zhonghua Fu Chan Ke Za Zhi; 2003 Mar 01; 38(3):158-61. PubMed ID: 12816691
    [Abstract] [Full Text] [Related]

  • 15. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
    Judson PL, Watson JM, Gehrig PA, Fowler WC, Haskill JS.
    Cancer Res; 1999 May 15; 59(10):2425-32. PubMed ID: 10344753
    [Abstract] [Full Text] [Related]

  • 16. Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells.
    Villedieu M, Louis MH, Dutoit S, Brotin E, Lincet H, Duigou F, Staedel C, Gauduchon P, Poulain L.
    Gynecol Oncol; 2007 Apr 15; 105(1):31-44. PubMed ID: 17275076
    [Abstract] [Full Text] [Related]

  • 17. Characterization of cell death events induced by anti-neoplastic drugs cisplatin, paclitaxel and 5-fluorouracil on human hepatoma cell lines: Possible mechanisms of cell resistance.
    Brenes O, Arce F, Gätjens-Boniche O, Díaz C.
    Biomed Pharmacother; 2007 Jul 15; 61(6):347-55. PubMed ID: 17399942
    [Abstract] [Full Text] [Related]

  • 18. Induction of p53 and drug resistance following treatment with cisplatin or paclitaxel in ovarian cancer cell lines.
    Metzinger DS, Taylor DD, Gercel-Taylor C.
    Cancer Lett; 2006 May 18; 236(2):302-8. PubMed ID: 15990222
    [Abstract] [Full Text] [Related]

  • 19. Tanshinone IIA acts via p38 MAPK to induce apoptosis and the down-regulation of ERCC1 and lung-resistance protein in cisplatin-resistant ovarian cancer cells.
    Jiao JW, Wen F.
    Oncol Rep; 2011 Mar 18; 25(3):781-8. PubMed ID: 21165580
    [Abstract] [Full Text] [Related]

  • 20. Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10.
    Stassi G, Todaro M, Zerilli M, Ricci-Vitiani L, Di Liberto D, Patti M, Florena A, Di Gaudio F, Di Gesù G, De Maria R.
    Cancer Res; 2003 Oct 15; 63(20):6784-90. PubMed ID: 14583474
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.